Clinical data | |
---|---|
Other names | AMG 133 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
MariTide, also known as maridebart cafraglutide [1] (developmental name AMG 133), is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor and an antagonist of the GIPR. In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested. [2] [3] [4]
Clinical data | |
---|---|
Other names | AMG 133 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
MariTide, also known as maridebart cafraglutide [1] (developmental name AMG 133), is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor and an antagonist of the GIPR. In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested. [2] [3] [4]